gamma-aminobutyric acid has been researched along with Psychotic Disorders in 106 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Psychotic Disorders: Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders." | 8.80 | Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999) |
| "Abnormal glutamate and GABA (gamma-aminobutyric acid) levels have been found in the early phase of schizophrenia and may underlie cognitive deficits." | 8.02 | Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis. ( Andersen, GS; Bojesen, KB; Broberg, BV; Edden, RAE; Fagerlund, B; Glenthøj, BY; Jessen, K; Larsson, HBW; Nielsen, MØ; Rostrup, E; Sigvard, A; Tangmose, K; Thomas, MB, 2021) |
| "In total, 56 antipsychotic-naïve patients with schizophrenia or psychotic disorder and 51 healthy control subjects underwent magnetic resonance spectroscopy to measure glutamate, glutamate+glutamine (Glx), and GABA levels in dorsal anterior cingulate cortex (ACC) and glutamate and Glx levels in left thalamus." | 8.02 | Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis. ( Andersen, GS; Bojesen, KB; Broberg, BV; Edden, RAE; Fagerlund, B; Glenthøj, BY; Jessen, K; Larsson, HBW; Nielsen, MØ; Rostrup, E; Sigvard, A; Tangmose, K; Thomas, MB, 2021) |
| "Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders." | 6.40 | Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999) |
| "Schizophrenia is accompanied by impaired cortical inhibition, as measured by several markers including the cortical silent period (CSP)." | 5.46 | Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study. ( Ceskova, E; Hublova, V; Kasparek, T; Mayerova, M; Prikrylova Kucerova, H; Ustohal, L, 2017) |
| "Abnormalities of GABAergic (gamma-aminobutyric acidergic) systems may play a role in schizophrenia and mood disorders." | 5.41 | Medial Frontal Cortex GABA Concentrations in Psychosis Spectrum and Mood Disorders: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies. ( Simmonite, M; Steeby, CJ; Taylor, SF, 2023) |
| "Ten patients with refractory partial epilepsy, previous mental retardation and psychosis or other significant psychiatric morbidity treated with vigabatrin were submitted periodically to specific tests (to quantify any possible change in behavioural parameters) and also to EEG recordings." | 5.09 | Vigabatrin use in psychotic epileptic patients: report of a prospective pilot study. ( Baldi, PL; De Agostini, G; Ferrari Ginevra, O; Lanzi, G; Muzio, C; Termine, C; Veggiotti, P, 1999) |
| "We review our current understanding of abnormal γ band oscillations in schizophrenia, their association with symptoms and the underlying cortical circuit abnormality, with a particular focus on the role of fast-spiking parvalbumin gamma-aminobutyric acid (GABA) neurons in the disease state." | 4.93 | Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities. ( McCarley, RW; McNally, JM, 2016) |
| " Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders." | 4.80 | Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999) |
| "Abnormal glutamate and GABA (gamma-aminobutyric acid) levels have been found in the early phase of schizophrenia and may underlie cognitive deficits." | 4.02 | Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis. ( Andersen, GS; Bojesen, KB; Broberg, BV; Edden, RAE; Fagerlund, B; Glenthøj, BY; Jessen, K; Larsson, HBW; Nielsen, MØ; Rostrup, E; Sigvard, A; Tangmose, K; Thomas, MB, 2021) |
| "In total, 56 antipsychotic-naïve patients with schizophrenia or psychotic disorder and 51 healthy control subjects underwent magnetic resonance spectroscopy to measure glutamate, glutamate+glutamine (Glx), and GABA levels in dorsal anterior cingulate cortex (ACC) and glutamate and Glx levels in left thalamus." | 4.02 | Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis. ( Andersen, GS; Bojesen, KB; Broberg, BV; Edden, RAE; Fagerlund, B; Glenthøj, BY; Jessen, K; Larsson, HBW; Nielsen, MØ; Rostrup, E; Sigvard, A; Tangmose, K; Thomas, MB, 2021) |
| "Psychotic disorders, such as schizophrenia, are characterized by prevalent and persistent executive deficits that are believed to be the result of dysfunctional inhibitory gamma-aminobutyric acid (GABA) processing of the prefrontal cortex (PFC)." | 3.83 | GABAergic mRNA expression is differentially expressed across the prelimbic and orbitofrontal cortices of rats sensitized to methamphetamine: Relevance to psychosis. ( Cornish, JL; Franklin, JL; Goodchild, AK; Parker, LM; Wearne, TA, 2016) |
| "The authors measured gamma-aminobutyric acid (GABA) levels in the lumbar CSF of patients with depression, with psychosis, or undergoing evaluation for a neurologic disorder." | 3.66 | GABA levels in CSF of patients with psychiatric disorders. ( Bowers, MB; Gold, BI; Roth, RH; Sweeney, DW, 1980) |
| "Gabapentin was effective in the treatment of mania and hypomania in patients with bipolar and schizoaffective disorders." | 2.69 | Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study. ( Cabras, PL; Carta, MG; Hardoy, MC; Hardoy, MJ, 1999) |
| "In DSM-5, catatonia syndrome may be diagnosed as a specifier to major mood disorders, psychotic disorders, general medical conditions, and as catatonia not otherwise specified." | 2.53 | Catatonia. ( Strik, W; Walther, S, 2016) |
| "Catatonia is potentially life threatening." | 2.53 | Catatonia. ( Strik, W; Walther, S, 2016) |
| "Brief postictal and alternating psychoses provide an opportunity to understand the complex relationships between epilepsy and schizophrenia-like brief psychotic episodes, and this understanding can assist in their management." | 2.44 | Alternating and postictal psychoses: review and a unifying hypothesis. ( Sachdev, PS, 2007) |
| "After adolescence, recurrent affective psychoses are relatively frequent, especially in patients with uniparental disomy." | 2.43 | Prader-Willi syndrome: atypical psychoses and motor dysfunctions. ( Tuinier, S; Verhoeven, WM, 2006) |
| "Differences between autism and catatonia of age-of-onset, symptoms, and illness course, do not exclude a common genetic etiology." | 2.42 | Autism as early expression of catatonia. ( Dhossche, DM, 2004) |
| "Reports indicate that catatonia often occurs in autism." | 2.42 | Autism as early expression of catatonia. ( Dhossche, DM, 2004) |
| "Several areas of overlap between autism and catatonia are found." | 2.42 | Autism as early expression of catatonia. ( Dhossche, DM, 2004) |
| "The literature on autism and catatonia are reviewed to identify areas of overlap." | 2.42 | Autism as early expression of catatonia. ( Dhossche, DM, 2004) |
| "Modern classificatory schemes define autism and catatonia separately and are not conducive to study areas of overlap." | 2.42 | Autism as early expression of catatonia. ( Dhossche, DM, 2004) |
| "Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders." | 2.40 | Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. ( Letterman, L; Markowitz, JS, 1999) |
| "Schizophrenia is the most prevalent form of psychosis, but this may also occur due to other medical conditions (e." | 2.40 | GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses. ( Keverne, EB, 1999) |
| "Schizophrenia is one of the most common and perhaps the most disabling of mental disorders, for which effective forms of treatment have not yet been established definitively." | 2.40 | Schizophrenia, psychosis, and the basal ganglia. ( Busatto, GF; Kerwin, RW, 1997) |
| "The underlying mechanisms of autism and schizophrenia are poorly understood, partly due to a lack of dimension-specific research." | 1.51 | The association of excitation and inhibition signaling with the relative symptom expression of autism and psychosis-proneness: Implications for psychopharmacology. ( Abu-Akel, A; Crewther, DP; Ford, TC, 2019) |
| "Stigmasterol treated animals showed significant decrease in locomotor activity, stereotypic behaviours, immobility duration and increased step down latency." | 1.48 | Protective effects of stigmasterol against ketamine-induced psychotic symptoms: Possible behavioral, biochemical and histopathological changes in mice. ( Dhingra, S; Jindal, DK; Parle, M; Yadav, M, 2018) |
| "Spermidine was significant to alleviate the ketamine-induced psychotic symptoms as indicated by decrease in locomotor activity in actophotometer, stereotypic behaviours, immobility duration in force swim test and latency to climb the pole in pole climb avoidance test." | 1.48 | Potential effect of spermidine on GABA, dopamine, acetylcholinesterase, oxidative stress and proinflammatory cytokines to diminish ketamine-induced psychotic symptoms in rats. ( Jindal, DK; Parle, M; Sharma, N; Yadav, M, 2018) |
| "Spermidine did not produce cataleptic effect on bar test at lower dose, but at the higher dose its cataleptic effect was similar to haloperidol." | 1.48 | Potential effect of spermidine on GABA, dopamine, acetylcholinesterase, oxidative stress and proinflammatory cytokines to diminish ketamine-induced psychotic symptoms in rats. ( Jindal, DK; Parle, M; Sharma, N; Yadav, M, 2018) |
| "Schizophrenia is characterized by a multiplicity of symptoms arising from almost all domains of mental function." | 1.48 | CSF GABA is reduced in first-episode psychosis and associates to symptom severity. ( Cervenka, S; Collste, K; Engberg, G; Erhardt, S; Fatouros-Bergman, H; Flyckt, L; Goiny, M; Malmqvist, A; Orhan, F; Piehl, F; Sellgren, CM; Victorsson, P, 2018) |
| "Gamma-aminobutyric acid levels were obtained from the medial prefrontal cortex using MEGA-PRESS and expressed as peak-area ratios relative to the synchronously acquired creatine signal." | 1.48 | Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms. ( Allen, P; Azis, M; Bonoldi, I; Bossong, M; Broome, M; Grace, AA; Horder, J; Howes, OD; Lythgoe, DJ; McGuire, P; Modinos, G; Murphy, DG; Perez, J; Simsek, F; Stone, JM, 2018) |
| "Gallic acid has been reported to possess a number of psychopharmacological activities." | 1.48 | Protective effect of gallic acid in experimental model of ketamine-induced psychosis: possible behaviour, biochemical, neurochemical and cellular alterations. ( Dhingra, MS; Dhingra, S; Jindal, DK; Kumar, A; Parle, M; Yadav, M, 2018) |
| "Schizophrenia is accompanied by impaired cortical inhibition, as measured by several markers including the cortical silent period (CSP)." | 1.46 | Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study. ( Ceskova, E; Hublova, V; Kasparek, T; Mayerova, M; Prikrylova Kucerova, H; Ustohal, L, 2017) |
| " Antipsychotic dosage was negatively correlated with GABA+ levels, but the on-off medication studies indicated no difference in GABA+ levels on antipsychotics compared with off antipsychotics." | 1.43 | Prefrontal GABA Levels Measured With Magnetic Resonance Spectroscopy in Patients With Psychosis and Unaffected Siblings. ( Apud, JA; Barnett, AS; Berman, KF; DeJong, K; Dickinson, D; Kuo, S; Marenco, S; Meyer, C; Shen, J; van der Veen, JW; Weinberger, DR, 2016) |
| "Schizophrenia is a neurodevelopmental disorder with altered expression of GABA-related genes in the prefrontal cortex (PFC)." | 1.42 | Altered cortical expression of GABA-related genes in schizophrenia: illness progression vs developmental disturbance. ( Bazmi, HH; Hoftman, GD; Lewis, DA; Li, S; Sampson, AR; Volk, DW, 2015) |
| "A patient with Usher syndrome and psychiatric symptoms is described and the difficulties in psychiatric assessment in her case are discussed." | 1.35 | Usher syndrome and psychiatric symptoms: a challenge in psychiatric management. ( Grubic, VN; Rijavec, N, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (14.15) | 18.7374 |
| 1990's | 11 (10.38) | 18.2507 |
| 2000's | 17 (16.04) | 29.6817 |
| 2010's | 40 (37.74) | 24.3611 |
| 2020's | 23 (21.70) | 2.80 |
| Authors | Studies |
|---|---|
| Li, W | 1 |
| Xu, J | 1 |
| Xiang, Q | 1 |
| Zhuo, K | 1 |
| Zhang, Y | 2 |
| Liu, D | 1 |
| Li, Y | 1 |
| Vinckier, F | 1 |
| Gaillard, R | 1 |
| Taylor, G | 1 |
| Murray, GK | 1 |
| Plaze, M | 1 |
| Bourdillon, P | 1 |
| Perin-Dureau, F | 1 |
| Simmonite, M | 2 |
| Steeby, CJ | 1 |
| Taylor, SF | 4 |
| Zahid, U | 1 |
| Onwordi, EC | 1 |
| Hedges, EP | 1 |
| Wall, MB | 1 |
| Modinos, G | 3 |
| Murray, RM | 1 |
| Egerton, A | 2 |
| Yao, B | 1 |
| Welsh, RC | 2 |
| Chen, X | 1 |
| Song, X | 1 |
| Öngür, D | 1 |
| Du, F | 1 |
| Mancini, V | 1 |
| Saleh, MG | 1 |
| Delavari, F | 1 |
| Bagautdinova, J | 1 |
| Eliez, S | 1 |
| Mishra, BR | 1 |
| Biswas, T | 1 |
| Sreeraj, VS | 1 |
| Nath, S | 1 |
| Mohapatra, D | 1 |
| Maiti, R | 1 |
| Bojesen, KB | 4 |
| Ebdrup, BH | 1 |
| Jessen, K | 2 |
| Sigvard, A | 2 |
| Tangmose, K | 2 |
| Edden, RAE | 4 |
| Larsson, HBW | 2 |
| Rostrup, E | 5 |
| Broberg, BV | 5 |
| Glenthøj, BY | 5 |
| Wenneberg, C | 3 |
| Hjorthøj, C | 3 |
| Buchardt Zingenberg, FJ | 1 |
| Glenthøj, LB | 3 |
| Nordentoft, M | 3 |
| Fagerlund, B | 3 |
| Krakauer, K | 2 |
| Kristensen, TD | 2 |
| Schwartz, C | 1 |
| Uçar, H | 1 |
| Gundogmus, İ | 1 |
| Bolu, A | 1 |
| Çelik, C | 1 |
| Kegeles, LS | 2 |
| de la Fuente-Sandoval, C | 4 |
| Wang, YM | 1 |
| Xiao, YH | 1 |
| Xie, WL | 1 |
| Sydnor, VJ | 1 |
| Roalf, DR | 1 |
| Thomas, MB | 1 |
| Nielsen, MØ | 1 |
| Andersen, GS | 1 |
| Heinze, K | 1 |
| Barron, HC | 1 |
| Howes, EK | 1 |
| Ramaswami, M | 1 |
| Broome, MR | 2 |
| Colijn, MA | 1 |
| Sonnenschein, SF | 1 |
| Grace, A | 1 |
| Quiñones, GM | 1 |
| Mayeli, A | 1 |
| Yushmanov, VE | 1 |
| Hetherington, HP | 1 |
| Ferrarelli, F | 1 |
| Loureiro, CM | 1 |
| da Roza, DL | 1 |
| Corsi-Zuelli, F | 1 |
| Shuhama, R | 1 |
| Fachim, HA | 1 |
| Simões-Ambrosio, LMC | 1 |
| Deminice, R | 1 |
| Jordão, AA | 1 |
| Menezes, PR | 1 |
| Del-Ben, CM | 1 |
| Louzada-Junior, P | 1 |
| Reid, MA | 3 |
| Yadav, M | 4 |
| Jindal, DK | 4 |
| Dhingra, MS | 1 |
| Kumar, A | 2 |
| Parle, M | 4 |
| Dhingra, S | 3 |
| Włodarczyk, A | 1 |
| Szarmach, J | 1 |
| Cubała, WJ | 1 |
| Wiglusz, MS | 1 |
| Simsek, F | 2 |
| Horder, J | 1 |
| Bossong, M | 2 |
| Bonoldi, I | 2 |
| Azis, M | 2 |
| Perez, J | 2 |
| Broome, M | 1 |
| Lythgoe, DJ | 2 |
| Stone, JM | 3 |
| Howes, OD | 2 |
| Murphy, DG | 1 |
| Grace, AA | 2 |
| Allen, P | 2 |
| McGuire, P | 2 |
| Reyes-Madrigal, F | 2 |
| Mao, X | 2 |
| León-Ortiz, P | 2 |
| Rodríguez-Mayoral, O | 2 |
| Jung-Cook, H | 1 |
| Solís-Vivanco, R | 2 |
| Graff-Guerrero, A | 2 |
| Shungu, DC | 2 |
| Sharma, N | 1 |
| Salibi, N | 2 |
| White, DM | 2 |
| Gawne, TJ | 2 |
| Denney, TS | 1 |
| Lahti, AC | 2 |
| Rowland, LM | 1 |
| Wijtenburg, SA | 1 |
| Samson, C | 1 |
| Quinn, B | 1 |
| Zelaya, F | 1 |
| Ford, TC | 1 |
| Abu-Akel, A | 1 |
| Crewther, DP | 1 |
| Da Silva, T | 1 |
| Hafizi, S | 1 |
| Rusjan, PM | 1 |
| Houle, S | 1 |
| Wilson, AA | 1 |
| Prce, I | 1 |
| Sailasuta, N | 1 |
| Mizrahi, R | 1 |
| Koshiyama, D | 1 |
| Kirihara, K | 1 |
| Tada, M | 1 |
| Nagai, T | 1 |
| Fujioka, M | 1 |
| Ichikawa, E | 1 |
| Ohta, K | 1 |
| Tani, M | 1 |
| Tsuchiya, M | 1 |
| Kanehara, A | 1 |
| Morita, K | 1 |
| Sawada, K | 1 |
| Matsuoka, J | 1 |
| Satomura, Y | 1 |
| Koike, S | 1 |
| Suga, M | 1 |
| Araki, T | 1 |
| Kasai, K | 1 |
| Overbeek, G | 1 |
| Kraguljac, NV | 1 |
| Wang, AM | 1 |
| Pradhan, S | 2 |
| Coughlin, JM | 1 |
| Trivedi, A | 1 |
| DuBois, SL | 1 |
| Crawford, JL | 1 |
| Sedlak, TW | 1 |
| Nucifora, FC | 1 |
| Nestadt, G | 1 |
| Nucifora, LG | 1 |
| Schretlen, DJ | 1 |
| Sawa, A | 1 |
| Barker, PB | 2 |
| Grove, TB | 1 |
| Ellingrod, VL | 1 |
| Tso, IF | 2 |
| Demeter, E | 1 |
| Phan, KL | 1 |
| Zamberletti, E | 1 |
| Beggiato, S | 1 |
| Steardo, L | 1 |
| Prini, P | 1 |
| Antonelli, T | 1 |
| Ferraro, L | 1 |
| Rubino, T | 1 |
| Parolaro, D | 1 |
| Hoftman, GD | 1 |
| Volk, DW | 2 |
| Bazmi, HH | 1 |
| Li, S | 1 |
| Sampson, AR | 2 |
| Lewis, DA | 2 |
| Radhakrishnan, R | 1 |
| Skosnik, PD | 1 |
| Cortes-Briones, J | 1 |
| Sewell, RA | 1 |
| Carbuto, M | 1 |
| Schnakenberg, A | 1 |
| Cahill, J | 1 |
| Bois, F | 1 |
| Gunduz-Bruce, H | 2 |
| Pittman, B | 2 |
| Ranganathan, M | 2 |
| D'Souza, DC | 2 |
| Ahn, KH | 1 |
| Sewell, A | 1 |
| Elander, J | 1 |
| Krystal, J | 1 |
| Powell, SB | 1 |
| Khan, A | 1 |
| Young, JW | 1 |
| Scott, CN | 1 |
| Buell, MR | 1 |
| Caldwell, S | 1 |
| Tsan, E | 1 |
| de Jong, LA | 1 |
| Acheson, DT | 1 |
| Lucero, J | 1 |
| Geyer, MA | 1 |
| Behrens, MM | 1 |
| Favila, R | 1 |
| Marenco, S | 2 |
| Meyer, C | 1 |
| Kuo, S | 1 |
| van der Veen, JW | 1 |
| Shen, J | 1 |
| DeJong, K | 1 |
| Barnett, AS | 1 |
| Apud, JA | 1 |
| Dickinson, D | 1 |
| Weinberger, DR | 1 |
| Berman, KF | 1 |
| McNally, JM | 1 |
| McCarley, RW | 1 |
| Brandt, AS | 1 |
| Unschuld, PG | 1 |
| Lim, IA | 1 |
| Churchill, G | 1 |
| Harris, AD | 1 |
| Hua, J | 1 |
| Ross, CA | 1 |
| van Zijl, PC | 1 |
| Edden, RA | 1 |
| Margolis, RL | 1 |
| Walther, S | 1 |
| Strik, W | 1 |
| Edelson, JR | 1 |
| Ustohal, L | 1 |
| Mayerova, M | 1 |
| Hublova, V | 1 |
| Prikrylova Kucerova, H | 1 |
| Ceskova, E | 1 |
| Kasparek, T | 1 |
| Wearne, TA | 1 |
| Parker, LM | 1 |
| Franklin, JL | 1 |
| Goodchild, AK | 1 |
| Cornish, JL | 1 |
| Uhlhaas, PJ | 1 |
| Gajwani, R | 1 |
| Gross, J | 1 |
| Gumley, AI | 1 |
| Lawrie, SM | 1 |
| Schwannauer, M | 1 |
| Orhan, F | 1 |
| Fatouros-Bergman, H | 1 |
| Goiny, M | 1 |
| Malmqvist, A | 1 |
| Piehl, F | 1 |
| Cervenka, S | 1 |
| Collste, K | 1 |
| Victorsson, P | 1 |
| Sellgren, CM | 1 |
| Flyckt, L | 1 |
| Erhardt, S | 1 |
| Engberg, G | 1 |
| Meyer, U | 1 |
| Feldon, J | 1 |
| Rijavec, N | 1 |
| Grubic, VN | 1 |
| Iizuka, T | 1 |
| Hara, A | 1 |
| Benes, FM | 1 |
| Kaufman, KR | 1 |
| Struck, PJ | 1 |
| Wu, B | 1 |
| Wong, S | 1 |
| Sotoing Taïwe, G | 1 |
| Ngo Bum, E | 1 |
| Talla, E | 1 |
| Dawe, A | 1 |
| Okomolo Moto, FC | 1 |
| Temkou Ngoupaye, G | 1 |
| Sidiki, N | 1 |
| Dabole, B | 1 |
| Djomeni Dzeufiet, PD | 1 |
| Dimo, T | 1 |
| De Waard, M | 1 |
| Palaniyappan, L | 1 |
| White, TP | 1 |
| Liddle, PF | 1 |
| Hardoy, MC | 3 |
| Carta, MG | 3 |
| Carpiniello, B | 1 |
| Cianchetti, C | 1 |
| Congia, S | 1 |
| D'Errico, I | 1 |
| Emanuelli, G | 1 |
| Garonna, F | 1 |
| Hardoy, MJ | 3 |
| Nardini, M | 1 |
| Kalkman, HO | 1 |
| Loetscher, E | 1 |
| FEITELEVICH, J | 1 |
| ZIPILIVAN, M | 1 |
| MORRONI, OB | 1 |
| Dhossche, DM | 1 |
| Philippe, A | 1 |
| Deron, J | 1 |
| Geneviève, D | 1 |
| de Lonlay, P | 1 |
| Gibson, KM | 1 |
| Rabier, D | 1 |
| Munnich, A | 1 |
| Verhoeven, WM | 1 |
| Tuinier, S | 1 |
| Tueting, P | 1 |
| Doueiri, MS | 1 |
| Guidotti, A | 1 |
| Davis, JM | 1 |
| Costa, E | 1 |
| Brummelte, S | 1 |
| Neddens, J | 1 |
| Teuchert-Noodt, G | 1 |
| Pilc, A | 1 |
| Ossowska, K | 1 |
| Sachdev, PS | 1 |
| Braun, I | 1 |
| Genius, J | 1 |
| Grunze, H | 1 |
| Bender, A | 1 |
| Möller, HJ | 1 |
| Rujescu, D | 1 |
| Huang, M | 1 |
| Li, Z | 1 |
| Dai, J | 1 |
| Shahid, M | 1 |
| Wong, EH | 1 |
| Meltzer, HY | 3 |
| Logothetis, J | 1 |
| Paraschos, A | 1 |
| Frangos, E | 1 |
| Bowers, MB | 3 |
| Heninger, GR | 1 |
| Sternberg, D | 1 |
| Post, RM | 1 |
| Sheard, MH | 1 |
| Meldrum, B | 1 |
| Arora, RC | 1 |
| Metz, J | 1 |
| Enna, SJ | 1 |
| Gold, BI | 2 |
| Roth, RH | 2 |
| van Kammen, DP | 1 |
| Sternberg, DE | 1 |
| Hare, TA | 1 |
| Waters, RN | 1 |
| Bunney, WE | 1 |
| Sweeney, DW | 1 |
| Sabatino, M | 1 |
| Cannizzaro, C | 1 |
| Flugy, A | 1 |
| Gagliand, M | 1 |
| Mineo, A | 1 |
| Cannizzaro, G | 1 |
| Devor, EJ | 1 |
| Waziri, R | 1 |
| Veggiotti, P | 2 |
| De Agostini, G | 2 |
| Baldi, PL | 2 |
| Muzio, C | 2 |
| Lanzi, G | 2 |
| Busatto, GF | 1 |
| Kerwin, RW | 1 |
| Termine, C | 1 |
| Ferrari Ginevra, O | 1 |
| Cabras, PL | 2 |
| Letterman, L | 1 |
| Markowitz, JS | 1 |
| Keverne, EB | 1 |
| Krishnamoorthy, ES | 1 |
| Trimble, MR | 1 |
| Casey, DE | 1 |
| Bennett, J | 1 |
| Goldman, WT | 1 |
| Suppes, T | 1 |
| Megna, JL | 1 |
| Devitt, PJ | 1 |
| Sauro, MD | 1 |
| Dewan, MJ | 1 |
| Bourne, JA | 1 |
| Costentin, J | 1 |
| Gerlach, J | 1 |
| Gillman, MA | 1 |
| Lichtigfeld, FJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Clinical Trial Examining Cognitive Remediation Plus Standard Treatment Versus Standard Treatment in Participants at Ultra-High Risk of Psychosis. - Effect on Cognitive Functioning, Functional Outcome and Symptomatology.[NCT02098408] | 146 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| Pan European Collaboration on Antipsychotic Naïve Schizophrenia II[NCT02339844] | Phase 4 | 130 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation[NCT03742557] | Phase 3 | 30 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| The Relationship Between the Efficacy of Lumateperone and Central Glutamate and Dopaminergic Metabolism: A Comparison With Risperidone in First Episode Psychosis[NCT05890768] | Phase 4 | 35 participants (Anticipated) | Interventional | 2023-05-11 | Recruiting | ||
| Use of Electroconvulsive Therapy to Treat Self-Injurious Behavior in Adults With Autism Spectrum Disorders[NCT03980366] | 1 participants (Actual) | Interventional | 2019-03-15 | Terminated (stopped due to We have not obtained additional subjects and chose to terminate/close this study.) | |||
| Combined PET and MR Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI[NCT05232955] | 40 participants (Anticipated) | Observational | 2022-02-28 | Not yet recruiting | |||
| Combined PET and MR Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 2: 7T MRI[NCT05233306] | 60 participants (Anticipated) | Observational | 2022-01-27 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
31 reviews available for gamma-aminobutyric acid and Psychotic Disorders
| Article | Year |
|---|---|
Medial Frontal Cortex GABA Concentrations in Psychosis Spectrum and Mood Disorders: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.
Topics: Frontal Lobe; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Mood Disorders; Proton Magnetic Resona | 2023 |
Neurofunctional correlates of glutamate and GABA imbalance in psychosis: A systematic review.
Topics: gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic Resonance Imaging; Psychotic Disorders; Sch | 2023 |
Paroxysmal dystonia and psychotic exacerbations in chronic psychosis: Diagnostic dilemmas and preliminary treatment approaches.
Topics: Antipsychotic Agents; Clozapine; Dystonia; gamma-Aminobutyric Acid; Humans; Psychotic Disorders | 2023 |
Cerebral glutamate and GABA levels in high-risk of psychosis states: A focused review and meta-analysis of
Topics: Frontal Lobe; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Prodromal Symptoms; Proton Magnetic Re | 2020 |
Metabolite abnormalities in psychosis risk: A meta-analysis of proton magnetic resonance spectroscopy studies.
Topics: gamma-Aminobutyric Acid; Glutamic Acid; Humans; Proton Magnetic Resonance Spectroscopy; Psychotic Di | 2020 |
A meta-analysis of ultra-high field glutamate, glutamine, GABA and glutathione 1HMRS in psychosis: Implications for studies of psychosis risk.
Topics: Adolescent; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Glutathione; Humans; Psychotic Disord | 2020 |
Impaired inhibitory processing: a new therapeutic target for autism and psychosis?
Topics: Autism Spectrum Disorder; Autistic Disorder; Brain; gamma-Aminobutyric Acid; Humans; Inhibition, Psy | 2021 |
The characterization of psychotic symptoms in succinic semialdehyde dehydrogenase deficiency: a review.
Topics: Adolescent; Age of Onset; Aggression; Amino Acid Metabolism, Inborn Errors; Anticonvulsants; Anxiety | 2020 |
Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.
Topics: Animals; Antipsychotic Agents; Dopamine; Drug Design; gamma-Aminobutyric Acid; Glutamates; Hippocamp | 2021 |
The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis.
Topics: Affect; Amygdala; Animals; Brain; Disease Models, Animal; gamma-Aminobutyric Acid; Hippocampus; Huma | 2019 |
Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities.
Topics: Animals; Cognition Disorders; gamma-Aminobutyric Acid; Humans; Neurons; Parvalbumins; Psychotic Diso | 2016 |
Catatonia.
Topics: Benzodiazepines; Catatonia; Diagnostic and Statistical Manual of Mental Disorders; Electroconvulsive | 2016 |
[Anti-NMDA receptor antibody-mediated encephalitis/encephalopathy].
Topics: Autoantibodies; Dyskinesias; Epitopes; Female; gamma-Aminobutyric Acid; Glutamates; Humans; Limbic E | 2009 |
Regulation of cell cycle and DNA repair in post-mitotic GABA neurons in psychotic disorders.
Topics: Adult; Cell Cycle; DNA Repair; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Neurons; Ps | 2011 |
The glutamate hypothesis of schizophrenia: neuroimaging and drug development.
Topics: Animals; Diagnostic Imaging; Drug Design; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Psychotic | 2012 |
The concept of salience network dysfunction in schizophrenia: from neuroimaging observations to therapeutic opportunities.
Topics: Cerebral Cortex; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Gyrus Cinguli; Humans; Magnetic R | 2012 |
GAD(67): the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis.
Topics: Animals; Brain; Dopamine; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Glutamine; Humans; Isoen | 2003 |
Autism as early expression of catatonia.
Topics: Adolescent; Age of Onset; Autistic Disorder; Catatonia; Cerebellum; Child; gamma-Aminobutyric Acid; | 2004 |
Prader-Willi syndrome: atypical psychoses and motor dysfunctions.
Topics: Adolescent; Adult; Female; gamma-Aminobutyric Acid; Humans; Male; Prader-Willi Syndrome; Psychomotor | 2006 |
Reelin down-regulation in mice and psychosis endophenotypes.
Topics: Animals; Behavior, Animal; Brain; Cell Adhesion Molecules, Neuronal; Disease Models, Animal; Down-Re | 2006 |
Alternating and postictal psychoses: review and a unifying hypothesis.
Topics: Brain; Electroencephalography; Epilepsy; gamma-Aminobutyric Acid; Humans; N-Methylaspartate; Psychot | 2007 |
Use of the anticonvulsant carbamazepine in primary and secondary affective illness: clinical and theoretical implications.
Topics: Affective Disorders, Psychotic; Animals; Antidepressive Agents; Antipsychotic Agents; Bipolar Disord | 1982 |
Clinical pharmacology of aggressive behavior.
Topics: Adolescent; Adult; Aged; Aggression; Anger; Anti-Anxiety Agents; Benzodiazepines; Brain Chemistry; C | 1984 |
GABA and acute psychoses.
Topics: Acute Disease; Animals; Brain; Cats; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Humans; Limbi | 1982 |
Schizophrenia, psychosis, and the basal ganglia.
Topics: Antipsychotic Agents; Basal Ganglia; Behavioral Symptoms; gamma-Aminobutyric Acid; Humans; Neuropsyc | 1997 |
Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions.
Topics: Acetates; Amines; Anticonvulsants; Anxiety; Bipolar Disorder; Cyclohexanecarboxylic Acids; Gabapenti | 1999 |
GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses.
Topics: Animals; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Interneurons; Psychoses, Substance-Induce | 1999 |
Forced normalization: clinical and therapeutic relevance.
Topics: Animals; Cats; Cerebral Cortex; Comorbidity; Diagnosis, Differential; Dopamine; Electroencephalograp | 1999 |
Tardive dyskinesia: pathophysiology and animal models.
Topics: Age Factors; Animals; Antipsychotic Agents; Basal Ganglia; Behavior, Animal; Disease Models, Animal; | 2000 |
SCH 23390: the first selective dopamine D1-like receptor antagonist.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain; Dopamine; Dop | 2001 |
SCH 23390: the first selective dopamine D1-like receptor antagonist.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain; Dopamine; Dop | 2001 |
SCH 23390: the first selective dopamine D1-like receptor antagonist.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain; Dopamine; Dop | 2001 |
SCH 23390: the first selective dopamine D1-like receptor antagonist.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Behavior, Animal; Benzazepines; Brain; Dopamine; Dop | 2001 |
[Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
Topics: Acetylcholine; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior; Corpus Stria | 1979 |
8 trials available for gamma-aminobutyric acid and Psychotic Disorders
| Article | Year |
|---|---|
Abnormal GABAergic function and negative affect in schizophrenia.
Topics: Adult; Cerebral Cortex; Cross-Over Studies; Female; GABA Modulators; gamma-Aminobutyric Acid; Humans | 2014 |
GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC.
Topics: Adolescent; Adult; Brain Mapping; Dissociative Disorders; Double-Blind Method; Dronabinol; Electroen | 2015 |
Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine.
Topics: Adolescent; Adult; Amphetamine; Cross-Over Studies; Double-Blind Method; Drug Administration Schedul | 2015 |
Gabapentin in antipsychotic-induced tardive dyskinesia: results of 1-year follow-up.
Topics: Acetates; Adult; Amines; Anticonvulsants; Antipsychotic Agents; Cyclohexanecarboxylic Acids; Dyskine | 2003 |
Use of the anticonvulsant carbamazepine in primary and secondary affective illness: clinical and theoretical implications.
Topics: Affective Disorders, Psychotic; Animals; Antidepressive Agents; Antipsychotic Agents; Bipolar Disord | 1982 |
Vigabatrin use in psychotic epileptic patients: report of a prospective pilot study.
Topics: Adolescent; Adult; Anticonvulsants; Behavioral Symptoms; Child; Child, Preschool; Drug Administratio | 1999 |
Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: results of an open-label study.
Topics: Acetates; Acute Disease; Adult; Aged; Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agent | 1999 |
Gabapentin's effect on agitation in severely and persistently mentally ill patients.
Topics: Acetates; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobuty | 2002 |
68 other studies available for gamma-aminobutyric acid and Psychotic Disorders
| Article | Year |
|---|---|
Neurometabolic and functional changes of default-mode network relate to clinical recovery in first-episode psychosis patients: A longitudinal
Topics: Antipsychotic Agents; Aspartic Acid; Brain; Brain Mapping; Default Mode Network; gamma-Aminobutyric | 2022 |
Acute psychosis following propofol in a patient with Parkinson disease: Effects of a γ-aminobutyric acid-dopamine imbalance.
Topics: Anesthetics, Intravenous; Dopamine; gamma-Aminobutyric Acid; Humans; Parkinson Disease; Propofol; Ps | 2022 |
Increased rostral medial frontal GABA+ in early psychosis is obscured by levels of negative affect.
Topics: Affect; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Psychotic Disorders; Schizophrenia | 2023 |
Association of default-mode network neurotransmitters and inter-network functional connectivity in first episode psychosis.
Topics: Brain; Brain Mapping; Default Mode Network; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic | 2023 |
Excitatory/Inhibitory Imbalance Underlies Hippocampal Atrophy in Individuals With 22q11.2 Deletion Syndrome With Psychotic Symptoms.
Topics: Atrophy; DiGeorge Syndrome; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Hippocampus; Humans; | 2023 |
Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Case-Control Studies; Female; gamma-Aminobutyric Acid; Glut | 2020 |
Cerebral Glutamate and Gamma-Aminobutyric Acid Levels in Individuals at Ultra-high Risk for Psychosis and the Association With Clinical Symptoms and Cognition.
Topics: Cognition; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Psychotic Disorders | 2020 |
Transient Psychosis After Low-Dose Pregabalin Discontinuation.
Topics: Analgesics; Anticonvulsants; gamma-Aminobutyric Acid; Humans; Pregabalin; Psychotic Disorders | 2022 |
Gamma-Aminobutyric Acid, Glutamate, and Cognition in Early Stages of Psychosis: Are We Closing the Gap?
Topics: Cognition; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Psychotic Disorders | 2020 |
Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12 months.
Topics: Adolescent; Adult; Brain Chemistry; Cognition; Cognitive Dysfunction; gamma-Aminobutyric Acid; Gluta | 2020 |
Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis.
Topics: Antipsychotic Agents; Cognition; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Gyrus Cinguli; H | 2021 |
Reduced GABA/glutamate in the thalamus of individuals at clinical high risk for psychosis.
Topics: Adolescent; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic Resonance Imaging; Psychotic Di | 2021 |
Plasma amino acids profile in first-episode psychosis, unaffected siblings and community-based controls.
Topics: Adult; Amino Acids; Antipsychotic Agents; Body Mass Index; Case-Control Studies; Cross-Sectional Stu | 2020 |
Glutamate and Gamma-Aminobutyric Acid Abnormalities in Antipsychotic-Naïve Patients With Schizophrenia: Evidence From Empirical and Meta-analytic Studies Using Magnetic Resonance Spectroscopy.
Topics: Antipsychotic Agents; Cognition; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnetic Resonance | 2021 |
Protective effect of gallic acid in experimental model of ketamine-induced psychosis: possible behaviour, biochemical, neurochemical and cellular alterations.
Topics: Animals; Antioxidants; Behavior, Animal; Brain; Disease Models, Animal; Female; Gallic Acid; gamma-A | 2018 |
Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy.
Topics: Antipsychotic Agents; Benzodiazepines; gamma-Aminobutyric Acid; Humans; Psychotic Disorders; Schizop | 2017 |
Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms.
Topics: Adolescent; Adult; gamma-Aminobutyric Acid; Humans; Male; Prefrontal Cortex; Prodromal Symptoms; Pro | 2018 |
Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aspartic Acid; Corpus Striatum; Female; gamma-Aminobutyric | 2018 |
Potential effect of spermidine on GABA, dopamine, acetylcholinesterase, oxidative stress and proinflammatory cytokines to diminish ketamine-induced psychotic symptoms in rats.
Topics: Acetylcholinesterase; Animals; Antipsychotic Agents; Brain; Cytokines; Dopamine; Female; gamma-Amino | 2018 |
7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.
Topics: Adult; Aspartic Acid; Cognitive Dysfunction; Female; gamma-Aminobutyric Acid; Glutamic Acid; Gyrus C | 2019 |
Magnetic Resonance Spectroscopy Gamma-Aminobutyric Acid: A Promising Biomarker for Antipsychotic Treatment?
Topics: Antipsychotic Agents; Biomarkers; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Spectroscopy; | 2018 |
Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis.
Topics: Adolescent; Adult; Biomarkers; Female; gamma-Aminobutyric Acid; Hippocampus; Humans; Magnetic Resona | 2018 |
Targeting oxidative stress, acetylcholinesterase, proinflammatory cytokine, dopamine and GABA by eucalyptus oil (Eucalyptus globulus) to alleviate ketamine-induced psychosis in rats.
Topics: Acetylcholinesterase; Animals; Cytokines; Dopamine; Eucalyptus; Eucalyptus Oil; gamma-Aminobutyric A | 2019 |
Protective effects of stigmasterol against ketamine-induced psychotic symptoms: Possible behavioral, biochemical and histopathological changes in mice.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Brain; Catalepsy; Disease Models, Animal; Dopamine; ga | 2018 |
The association of excitation and inhibition signaling with the relative symptom expression of autism and psychosis-proneness: Implications for psychopharmacology.
Topics: Adolescent; Adult; Autistic Disorder; Female; Follow-Up Studies; Functional Laterality; gamma-Aminob | 2019 |
GABA levels and TSPO expression in people at clinical high risk for psychosis and healthy volunteers: a PET-MRS study.
Topics: Adolescent; Adult; Anilides; Cross-Sectional Studies; Female; gamma-Aminobutyric Acid; Humans; Male; | 2019 |
Electrophysiological evidence for abnormal glutamate-GABA association following psychosis onset.
Topics: Acoustic Stimulation; Adult; Brain; Electroencephalography; Evoked Potentials, Auditory; Female; Gam | 2018 |
Relationship Between Cortical Excitation and Inhibition and Task-Induced Activation and Deactivation: A Combined Magnetic Resonance Spectroscopy and Functional Magnetic Resonance Imaging Study at 7T in First-Episode Psychosis.
Topics: Adult; Brain; Cortical Excitability; Female; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magneti | 2019 |
Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.
Topics: Aspartic Acid; Brain; Case-Control Studies; Cross-Sectional Studies; Dipeptides; Female; gamma-Amino | 2019 |
Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like phenotype induced by adolescent delta-9-tetrahydrocannabinol exposure in rats.
Topics: Age Factors; Animals; Animals, Newborn; Cannabinoid Receptor Agonists; Disease Models, Animal; Dose- | 2014 |
Altered cortical expression of GABA-related genes in schizophrenia: illness progression vs developmental disturbance.
Topics: Adult; Animals; Calbindin 2; Case-Control Studies; Disease Progression; Female; GABA Plasma Membrane | 2015 |
Early Adolescent Emergence of Reversal Learning Impairments in Isolation-Reared Rats.
Topics: Age Factors; Animals; Behavior, Animal; Cognition Disorders; Disease Models, Animal; Female; gamma-A | 2015 |
Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy.
Topics: Corpus Striatum; Female; gamma-Aminobutyric Acid; Genetic Predisposition to Disease; Glutamic Acid; | 2015 |
Prefrontal GABA Levels Measured With Magnetic Resonance Spectroscopy in Patients With Psychosis and Unaffected Siblings.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Female; gamma-Aminobutyric Acid; Gyrus Cinguli; H | 2016 |
Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A (1)H MRS Study at 7 Tesla.
Topics: Adult; Aging; Antipsychotic Agents; Aspartic Acid; Choline; Creatine; Dipeptides; Female; gamma-Amin | 2016 |
Brain GABA Function and Psychosis.
Topics: Brain; gamma-Aminobutyric Acid; Humans; Psychotic Disorders | 2016 |
Cortical GABA markers identify a molecular subtype of psychotic and bipolar disorders.
Topics: Adult; Biomarkers; Bipolar Disorder; Female; GABAergic Neurons; gamma-Aminobutyric Acid; Glutamate D | 2016 |
Response to de la Fuente-Sandoval: Challenges Measuring GABA Levels in Patients With Psychosis.
Topics: gamma-Aminobutyric Acid; Humans; Psychotic Disorders | 2016 |
Potential Regional Differences in GABA Levels in Patients With Psychosis Compared With Control Subjects.
Topics: gamma-Aminobutyric Acid; Humans; Psychotic Disorders; Schizophrenia | 2016 |
Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study.
Topics: Adult; Antipsychotic Agents; Cerebral Cortex; gamma-Aminobutyric Acid; Humans; Neural Inhibition; Ps | 2017 |
GABAergic mRNA expression is differentially expressed across the prelimbic and orbitofrontal cortices of rats sensitized to methamphetamine: Relevance to psychosis.
Topics: Animals; GABA Plasma Membrane Transport Proteins; gamma-Aminobutyric Acid; Glutamate Decarboxylase; | 2016 |
The Youth Mental Health Risk and Resilience Study (YouR-Study).
Topics: Adolescent; Adult; Biomarkers; Brain; Clinical Protocols; Early Diagnosis; Female; gamma-Aminobutyri | 2017 |
CSF GABA is reduced in first-episode psychosis and associates to symptom severity.
Topics: Adult; Antipsychotic Agents; Brain; Case-Control Studies; Chromatography, High Pressure Liquid; Fema | 2018 |
Neural basis of psychosis-related behaviour in the infection model of schizophrenia.
Topics: Animals; Avoidance Learning; Brain; Disease Models, Animal; Dopamine; Female; gamma-Aminobutyric Aci | 2009 |
Usher syndrome and psychiatric symptoms: a challenge in psychiatric management.
Topics: Adult; Anorexia Nervosa; Anti-Anxiety Agents; Antipsychotic Agents; Clozapine; Comorbidity; Diagnosi | 2009 |
Off-label gabapentin masking ictal triphasic waves: case analysis of neuropsychiatric and electrographic correlates.
Topics: Administration, Oral; Aged; Amines; Anticonvulsants; Brain Waves; Cyclohexanecarboxylic Acids; Elect | 2011 |
Antipsychotic and sedative effects of the leaf extract of Crassocephalum bauchiense (Hutch.) Milne-Redh (Asteraceae) in rodents.
Topics: Animals; Antipsychotic Agents; Apomorphine; Asteraceae; Behavior, Animal; Body Temperature; Brain; C | 2012 |
[Effects of gamma-aminobutyric acid-pyridoxine in presenile and senile psychiatric disorders].
Topics: Amino Acids; Dementia; gamma-Aminobutyric Acid; Humans; Mental Disorders; Psychotic Disorders; Pyrid | 1962 |
[IMMEDIATE CLINICAL RESULTS WITH GAMMA AMINOBUTYRIC ACID B6 IN SCHIZOPHRENIAS AND DELIRIUMS].
Topics: Aminobutyrates; Biochemical Phenomena; Biochemistry; Delirium; gamma-Aminobutyric Acid; Mental Disor | 1963 |
Neurodevelopmental pattern of succinic semialdehyde dehydrogenase deficiency (gamma-hydroxybutyric aciduria).
Topics: Adolescent; Aldehyde Oxidoreductases; Child, Preschool; Developmental Disabilities; gamma-Aminobutyr | 2004 |
Alteration in the GABAergic network of the prefrontal cortex in a potential animal model of psychosis.
Topics: Aging; Animals; Cell Differentiation; Disease Models, Animal; Dopamine Uptake Inhibitors; Environmen | 2007 |
Metabotropic glutamate receptors.
Topics: Animals; Antipsychotic Agents; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Ligands; Models, Biol | 2007 |
Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; gamma-Aminobutyric Acid; | 2007 |
Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Brain Chemistry; Dibenzocycloheptenes; Dopamine; Dose- | 2008 |
Side effects in preventive maintenance therapy with neuroleptics with special emphasis on tardive dyskinesia.
Topics: Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Pa | 1981 |
Clinical processes and central dopaminergic activity in psychotic disorders.
Topics: Adolescent; Adult; Antipsychotic Agents; Dopamine; Female; gamma-Aminobutyric Acid; Homovanillic Aci | 1980 |
Biological studies of schizoaffective disorders.
Topics: Blood Platelets; Catechol O-Methyltransferase; Dexamethasone; Dopamine; Dopamine beta-Hydroxylase; g | 1984 |
GABA and neuropsychiatric disorders.
Topics: Animals; Basal Ganglia; Central Nervous System Diseases; Epilepsies, Myoclonic; Epilepsies, Partial; | 1980 |
CSF GABA in psychotic disorders.
Topics: Adolescent; Adult; Female; gamma-Aminobutyric Acid; Haloperidol; Homovanillic Acid; Humans; Male; Mi | 1980 |
CSF levels of gamma-aminobutyric acid in schizophrenia. Low values in recently ill patients.
Topics: Adult; Double-Blind Method; Female; gamma-Aminobutyric Acid; Humans; Male; Pimozide; Psychotic Disor | 1982 |
GABA levels in CSF of patients with psychiatric disorders.
Topics: Adult; Aged; Bipolar Disorder; Depression; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Age | 1980 |
NMDA-GABA interactions in an animal model of behaviour: a gating mechanism from motivation toward psychotic-like symptoms.
Topics: Alprazolam; Animals; Behavior, Animal; Desipramine; Disease Models, Animal; Dizocilpine Maleate; gam | 1994 |
A familial/genetic study of plasma serine and glycine concentrations.
Topics: Dopamine; Female; gamma-Aminobutyric Acid; Glucose; Glutamates; Glycine; Humans; Internal-External C | 1993 |
Vigabatrin and psychosis: is there a true correlation?
Topics: Anticonvulsants; Electroencephalography; Epilepsies, Partial; gamma-Aminobutyric Acid; Humans; Psych | 1997 |
Gabapentin as a promising treatment for antipsychotic-induced movement disorders in schizoaffective and bipolar patients.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Antipsychotic Agents; Bipolar Disorder; Cyclohexanecar | 1999 |
Gabapentin for treatment of bipolar and schizoaffective disorders.
Topics: Acetates; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Female; Ga | 1997 |
Pathophysiological mechanisms underlying tardive dyskinesia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Brain; Dyskinesia, Drug-Induced; gamma-Aminobutyric Ac | 1985 |
The opioids and the GABA-ergic differentiation of the psychoses.
Topics: gamma-Aminobutyric Acid; Humans; Nitrous Oxide; Psychotic Disorders | 1986 |